Rallybio Gets Clearance for Phase 2 Alloimunization Study in Europe, UK

MT Newswires Live10-29

Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant women at higher risk of developing HPA-1a alloimmunization, which can lead to fetal and neonatal alloimmune thrombocytopenia.

With the approvals, the company said it intends to initiate screening of participants in Q4.

Rallybio said the phase 2 dose confirmation study will evaluate the safety and pharmacokinetics of RLYB212 in a total of eight pregnant women in Belgium, the Netherlands, Norway, Sweden, and the UK.

Shares of the company were up 1.9% in recent Tuesday trading.

Price: 1.06, Change: +0.02, Percent Change: +1.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479719282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479719282","market":"us","top_or_hot":-1,"title":"Rallybio Gets Clearance for Phase 2 Alloimunization Study in Europe, UK","media":"MT Newswires Live","content":"<html><body><p> Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant women at higher risk of developing HPA-1a alloimmunization, which can lead to fetal and neonatal alloimmune thrombocytopenia.</p><p>With the approvals, the company said it intends to initiate screening of participants in Q4.</p><p>Rallybio said the phase 2 dose confirmation study will evaluate the safety and pharmacokinetics of RLYB212 in a total of eight pregnant women in Belgium, the Netherlands, Norway, Sweden, and the UK.</p><p>Shares of the company were up 1.9% in recent Tuesday trading.</p><p>Price: 1.06, Change: +0.02, Percent Change: +1.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rallybio Gets Clearance for Phase 2 Alloimunization Study in Europe, UK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRallybio Gets Clearance for Phase 2 Alloimunization Study in Europe, UK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 23:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479719282","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479719282","pubTimestamp":1730214550,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant wo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","RLYB":"Rallybio Corp."},"translate_title":"Rallybio在欧洲和英国获得2期同种免疫研究许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":1},"content_text":"Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant women at higher risk of developing HPA-1a alloimmunization, which can lead to fetal and neonatal alloimmune thrombocytopenia.With the approvals, the company said it intends to initiate screening of participants in Q4.Rallybio said the phase 2 dose confirmation study will evaluate the safety and pharmacokinetics of RLYB212 in a total of eight pregnant women in Belgium, the Netherlands, Norway, Sweden, and the UK.Shares of the company were up 1.9% in recent Tuesday trading.Price: 1.06, Change: +0.02, Percent Change: +1.92","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479719282"}